Join us for an informational webcast to learn about Flamel’s REST-ON Phase III clinical study of once-nightly sodium oxybate (FT 218)

SAVE THE DATE

Saturday, April 7, 2018

2:00 p.m. EDT

Watch this page to learn how you can register to join this meeting.

 

What can you do to REST-ON?

Join us for an informational webcast to learn about Flamel’s REST-ON Phase III clinical study of once-nightly sodium oxybate (FT 218)

Our agenda features a panel of experts on FT 218, narcolepsy, sleep research, and leaders from patient advocacy groups

Presenters:

  • Dr. Thomas Roth, PhD, Director of Sleep Disorders & Research Center, Henry Ford
  • Dr. David Monteith, VP, Research & Development, Avadel Pharmaceuticals (Flamel)
  • Julie Flygare, Founder, Project Sleep
  • Dr. Eveline Honig, Executive Director, Narcolepsy Network

 

www.rethinknarcolepsy.com

Follow us on Twitter: @AvadelPharma